We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
Effective development of therapies in rare diseases such as cystic fibrosis relies on the involvement of physicians working in specialised clinics. These clinicians are then able to offer participation in such research projects to patients under their care. By offering training in clinical research best practice, SIFC hopes that physicians and their teams may be able to engage even more in future clinical research programs and offer participation to more patients with cystic fibrosis. As recognised experts in clinical research, with strong experience in cystic fibrosis, CROMSOURCE is wellplaced to support this work. During the course, CROMSOURCE personnel are training physicians and their teams on topics including typical aspects of a clinical research study protocol, the responsibilities of the physician and clinical staff who are involved in clinical research and the regulatory application and approval process for clinical research.
Oriana Zerbini MD, founder and Chief Executive Officer of CROMSOURCE noted "We are delighted to take part in this initiative and work alongside representatives from the Italian ISS (National High Health Commission), the US Cystic Fibrosis Foundation, Ethics Committees and various pharmaceutical companies. CROMSOURCE is committed to sharing our expertise in clinical research and fully recognise the importance of this training course. In this spirit we have pleasure in supporting this important initiative".
About CROMSOURCE: Founded in 1994, CROMSOURCE is the leading independent provider of international outsourced services to the pharmaceutical, biotechnology and medical device industries, specialised in clinical development and staffing solutions across Europe and North America. CROMSOURCE is unique in providing clients with a guarantee that projects will be delivered according to agreed timelines and within the original contract budget.